Profile: Aimmune Therapeutics Inc (AIMT.O)
Aimmune Therapeutics, Inc., incorporated on June 24, 2011, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy.
The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. For patients in the up-dosing phase of the AR101 treatment regimen, AR101 would be provided in a series of color coded pharmaceutical grade capsules of various dose levels. The Company's first clinical trial of AR101, ARC001, was a randomized, multi-center, double-blind, placebo controlled Phase II trial of AR101 for the treatment of peanut allergy. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.
The Company competes with DBV Technologies S.A.
Aimmune Therapeutics Inc
8000 Marina Blvd Ste 300
BRISBANE CA 94005-1884